Medpace Holdings, Inc. (NASDAQ:MEDP) Given Consensus Recommendation of “Hold” by Analysts

Medpace Holdings, Inc. (NASDAQ:MEDP) has earned an average rating of “Hold” from the fourteen brokerages that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $483.4545.

A number of equities research analysts have weighed in on MEDP shares. Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target on the stock in a research report on Friday, February 13th. Mizuho set a $582.00 price objective on Medpace in a research report on Wednesday, February 11th. Weiss Ratings restated a “buy (b)” rating on shares of Medpace in a research report on Wednesday, January 28th. TD Cowen raised Medpace from a “sell” rating to a “hold” rating and cut their target price for the stock from $462.00 to $419.00 in a research note on Wednesday. Finally, Leerink Partners decreased their price target on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a research note on Wednesday, February 11th.

Insider Buying and Selling at Medpace

In other Medpace news, VP Susan E. Burwig sold 20,000 shares of the company’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the completion of the sale, the vice president directly owned 27,500 shares in the company, valued at $16,751,625. This represents a 42.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO August J. Troendle sold 668 shares of the firm’s stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $590.69, for a total value of $394,580.92. Following the transaction, the chief executive officer directly owned 646,184 shares in the company, valued at $381,694,426.96. This trade represents a 0.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 201,745 shares of company stock valued at $122,369,738 over the last three months. 20.30% of the stock is currently owned by insiders.

Institutional Trading of Medpace

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Quent Capital LLC bought a new position in shares of Medpace in the third quarter worth approximately $25,000. Optiver Holding B.V. purchased a new position in shares of Medpace in the third quarter valued at about $27,000. Steigerwald Gordon & Koch Inc. purchased a new position in shares of Medpace in the fourth quarter valued at about $30,000. Elyxium Wealth LLC bought a new position in shares of Medpace during the fourth quarter valued at about $30,000. Finally, Quarry LP purchased a new stake in shares of Medpace during the third quarter worth about $35,000. Institutional investors own 77.98% of the company’s stock.

Medpace Price Performance

Shares of MEDP opened at $453.77 on Monday. Medpace has a 1-year low of $250.05 and a 1-year high of $628.92. The company has a market capitalization of $12.88 billion, a P/E ratio of 29.66, a P/E/G ratio of 2.14 and a beta of 1.42. The firm’s 50 day simple moving average is $556.01 and its 200 day simple moving average is $537.96.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, February 9th. The company reported $4.67 EPS for the quarter, topping analysts’ consensus estimates of $4.18 by $0.49. The business had revenue of $708.45 million during the quarter, compared to analysts’ expectations of $689.53 million. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The business’s quarterly revenue was up 32.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities analysts anticipate that Medpace will post 12.29 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.